Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Michigan

Phase 3 cancer trials in Michigan

116 Phase 3 cancer studies are recruiting participants at sites in 59 cities across Michigan as of November 18, 2026, according to ClinicalTrials.gov.

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Browse Michigan by city

Cities with the most studies recruiting right now.

Every Michigan city with a recruiting study

By research area: Lung Cancer (31), Breast Cancer (30), Lymphoma (24), Prostate Cancer (17), Melanoma (7), Pancreatic Cancer (7).

Detroit (66), Grand Rapids (55), Ann Arbor (46), Brighton (28), Lansing (28), Pontiac (27), Ypsilanti (27), Chelsea (26), Canton (25), Livonia (25), Flint (24), Kalamazoo (23), Traverse City (23), Dearborn (22), Wyoming (22), Clinton Township (21), Novi (20), West Bloomfield (20), Saint Joseph (19), Battle Creek (18), Brownstown (18), Farmington Hills (18), Niles (18), Reed City (18), Royal Oak (18), Jackson (17), Saginaw (17), Macomb (16), Clarkston (15), Wyandotte (15), Tawas City (14), Troy (13), Escanaba (12), Southfield (12), Warren (12), East China Township (10), Grosse Pointe Woods (10), Muskegon (10), Norton Shores (10), Mount Pleasant (8), Bay City (6), Lapeer (6), Manistique (5), Midland (5), Mount Clemens (5), Petoskey (5), Alma (4), Alpena (4), Gladwin (4), Port Huron (4), Madison Heights (3), Sterling Heights (3), Holland (2), Marquette (2), Big Rapids (1), Caro (1), Iron Mountain (1), Marlette (1), West Branch (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Breast cancer: recently updated in Michigan

Basic details from each study's public record (the 12 most recently updated of 116). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Ann Arbor · Detroit
    Registry record
    NCT06393374 · updated
  2. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Brighton · Brownstown · Canton · and 15 more U.S. locations
    Registry record
    NCT07391774 · updated
  3. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Grand Rapids
    Registry record
    NCT06841354 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Michigan on ClinicalTrials.gov.

Lung cancer: recently updated in Michigan

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Ann Arbor · Battle Creek · Brighton · and 27 more U.S. locations
    Registry record
    NCT06498635 · updated
  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Recruiting in
    Ann Arbor · Detroit
    Registry record
    NCT06767514 · updated
  3. Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Battle Creek · Grand Rapids · Kalamazoo · and 5 more U.S. locations
    Registry record
    NCT07388524 · updated
  4. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Ypsilanti
    Registry record
    NCT06422143 · updated
  5. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Mirati Therapeutics Inc.
    Recruiting in
    Detroit
    Registry record
    NCT06875310 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Michigan on ClinicalTrials.gov.

Lymphoma: recently updated in Michigan

  1. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Ann Arbor · Battle Creek · Brighton · and 27 more U.S. locations
    Registry record
    NCT06337318 · updated
  2. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Nuvation Bio Inc.
    Recruiting in
    Detroit
    Registry record
    NCT05303519 · updated
  3. A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Grand Rapids
    Registry record
    NCT06136559 · updated
  4. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Recruiting in
    Detroit · Farmington Hills
    Registry record
    NCT06724237 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Michigan on ClinicalTrials.gov.

Ask about studies in Michigan

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call